Tumor-focused Parabilis raises $305M to upend status quo Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a pivotal push for its potential first-in-class cancer drug
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable . . . Founded as FogPharma in 2015 by serial biotech entrepreneur Gregory Verdine, Parabilis has raised more than $800 million in private funding and has so far spent nearly $600 million on drug research, according to its IPO filing
Parabilis Medicines | The Pharma Letter | The Pharmaletter Formerly known as FogPharma, the company rebranded as Parabilis Medicines to reflect its evolution toward a broader pipeline and clinical identity Parabilis is focused exclusively on oncology, pursuing targets that small molecules and biologics have repeatedly failed to engage
Government Contract Financing | Parabilis We provide financial partnerships for government contractors in winning federal contract bids and extending business lines of credit